Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 43 entries
Sorted by: Best Match Show Resources per page
HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours.

Hereditary cancer in clinical practice

Brozek I, Kardaś I, Ochman K, Debniak J, Stukan M, Ratajska M, Morzuch L, Emerich J, Limon J.
PMID: 20223002
Hered Cancer Clin Pract. 2006 Nov 15;4(1):39-42. doi: 10.1186/1897-4287-4-1-39.

Whereas HER2 amplification is a well-known phenomenon in breast tumours, its frequency and clinical importance in ovarian cancer have not been established. The aim of the study was to compare the frequency of HER2 amplification in hereditary (BRCA-positive) and...

Cite
Brozek I, Kardaś I, Ochman K, et al. HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours. Hered Cancer Clin Pract. 2006;4(1):39-42doi: 10.1186/1897-4287-4-1-39.
Brozek, I., Kardaś, I., Ochman, K., Debniak, J., Stukan, M., Ratajska, M., Morzuch, L., Emerich, J., & Limon, J. (2006). HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours. Hereditary cancer in clinical practice, 4(1), 39-42. https://doi.org/10.1186/1897-4287-4-1-39
Brozek, Izabela, et al. "HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours." Hereditary cancer in clinical practice vol. 4,1 (2006): 39-42. doi: https://doi.org/10.1186/1897-4287-4-1-39
Brozek I, Kardaś I, Ochman K, Debniak J, Stukan M, Ratajska M, Morzuch L, Emerich J, Limon J. HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours. Hered Cancer Clin Pract. 2006 Nov 15;4(1):39-42. doi: 10.1186/1897-4287-4-1-39. PMID: 20223002; PMCID: PMC3401919.
Copy Download .nbib Format: NLM
Postoperative evaluation of hydronephrosis due to the way of pyeloplasy (dismembered / non-dismembered).

Central European journal of urology

Matuszewski M, Drewniak T, Juszczak K.
PMID: 24982796
Cent European J Urol. 2014;67(1):106-7. doi: 10.5173/ceju.2014.01.art25.

No abstract available.

Cite
Matuszewski M, Drewniak T, Juszczak K. Postoperative evaluation of hydronephrosis due to the way of pyeloplasy (dismembered / non-dismembered). Cent European J Urol. 2014;67(1):106-7doi: 10.5173/ceju.2014.01.art25.
Matuszewski, M., Drewniak, T., & Juszczak, K. (2014). Postoperative evaluation of hydronephrosis due to the way of pyeloplasy (dismembered / non-dismembered). Central European journal of urology, 67(1), 106-7. https://doi.org/10.5173/ceju.2014.01.art25
Matuszewski, Marcin, et al. "Postoperative evaluation of hydronephrosis due to the way of pyeloplasy (dismembered / non-dismembered)." Central European journal of urology vol. 67,1 (2014): 106-7. doi: https://doi.org/10.5173/ceju.2014.01.art25
Matuszewski M, Drewniak T, Juszczak K. Postoperative evaluation of hydronephrosis due to the way of pyeloplasy (dismembered / non-dismembered). Cent European J Urol. 2014;67(1):106-7. doi: 10.5173/ceju.2014.01.art25. PMID: 24982796; PMCID: PMC4074731.
Copy Download .nbib Format: NLM
Prognostic factors of overall survival in renal cancer patients - single oncological center study.

Central European journal of urology

Drewniak T, Sandheim M, Jakubowski J, Juszczak K, Stelmach AW.
PMID: 24707365
Cent European J Urol. 2013;66(3):283-91. doi: 10.5173/ceju.2013.03.art9. Epub 2013 Nov 18.

INTRODUCTION: The clinical course of renal cancer remains difficult to predict. Attempts to appoint new independent prognostic factors (IPFs) and comparisons of already identified ones among populations are inevitable to develop more effective prognostic instruments. The aim of this...

Cite
Drewniak T, Sandheim M, Jakubowski J, et al. Prognostic factors of overall survival in renal cancer patients - single oncological center study. Cent European J Urol. 2013;66(3):283-91doi: 10.5173/ceju.2013.03.art9.
Drewniak, T., Sandheim, M., Jakubowski, J., Juszczak, K., & Stelmach, A. W. (2013). Prognostic factors of overall survival in renal cancer patients - single oncological center study. Central European journal of urology, 66(3), 283-91. https://doi.org/10.5173/ceju.2013.03.art9
Drewniak, Tomasz, et al. "Prognostic factors of overall survival in renal cancer patients - single oncological center study." Central European journal of urology vol. 66,3 (2013): 283-91. doi: https://doi.org/10.5173/ceju.2013.03.art9
Drewniak T, Sandheim M, Jakubowski J, Juszczak K, Stelmach AW. Prognostic factors of overall survival in renal cancer patients - single oncological center study. Cent European J Urol. 2013;66(3):283-91. doi: 10.5173/ceju.2013.03.art9. Epub 2013 Nov 18. PMID: 24707365; PMCID: PMC3974466.
Copy Download .nbib Format: NLM
Dupuytren's disease and the risk of malignant neoplasms.

Hereditary cancer in clinical practice

Zyluk A, Paszkowska-Szczur K, Gupta S, Scott RJ, Lubiński J, Dębniak T.
PMID: 24598251
Hered Cancer Clin Pract. 2014 Mar 06;12(1):6. doi: 10.1186/1897-4287-12-6.

The object of this study was the investigation of the risk of occurrence of malignant neoplasms in 508 patients with Dupuytren's disease (DD) and in 2157 of their 1st degree relatives. In the first stage of the study, we...

Cite
Zyluk A, Paszkowska-Szczur K, Gupta S, et al. Dupuytren's disease and the risk of malignant neoplasms. Hered Cancer Clin Pract. 2014;12(1):6doi: 10.1186/1897-4287-12-6.
Zyluk, A., Paszkowska-Szczur, K., Gupta, S., Scott, R. J., Lubiński, J., & Dębniak, T. (2014). Dupuytren's disease and the risk of malignant neoplasms. Hereditary cancer in clinical practice, 12(1), 6. https://doi.org/10.1186/1897-4287-12-6
Zyluk, Andrzej, et al. "Dupuytren's disease and the risk of malignant neoplasms." Hereditary cancer in clinical practice vol. 12,1 (2014): 6. doi: https://doi.org/10.1186/1897-4287-12-6
Zyluk A, Paszkowska-Szczur K, Gupta S, Scott RJ, Lubiński J, Dębniak T. Dupuytren's disease and the risk of malignant neoplasms. Hered Cancer Clin Pract. 2014 Mar 06;12(1):6. doi: 10.1186/1897-4287-12-6. PMID: 24598251; PMCID: PMC3973858.
Copy Download .nbib Format: NLM
Tailoring Properties of Resol Resin-Derived Spherical Carbons for Adsorption of Phenol from Aqueous Solution.

Molecules (Basel, Switzerland)

Sidor K, Berniak T, Łątka P, Rokicińska A, Michalik M, Kuśtrowski P.
PMID: 33808858
Molecules. 2021 Mar 19;26(6). doi: 10.3390/molecules26061736.

The polycondensation of resorcinol and formaldehyde in a water-ethanol mixture using the adapted Stöber method was used to obtain resol resins. An optimization of synthesis conditions and the use of an appropriate stabilizer (e.g., poly(vinyl alcohol)) resulted in spherical...

Cite
Sidor K, Berniak T, Łątka P, et al. Tailoring Properties of Resol Resin-Derived Spherical Carbons for Adsorption of Phenol from Aqueous Solution. Molecules. 2021;26(6)doi: 10.3390/molecules26061736.
Sidor, K., Berniak, T., Łątka, P., Rokicińska, A., Michalik, M., & Kuśtrowski, P. (2021). Tailoring Properties of Resol Resin-Derived Spherical Carbons for Adsorption of Phenol from Aqueous Solution. Molecules (Basel, Switzerland), 26(6), . https://doi.org/10.3390/molecules26061736
Sidor, Karol, et al. "Tailoring Properties of Resol Resin-Derived Spherical Carbons for Adsorption of Phenol from Aqueous Solution." Molecules (Basel, Switzerland) vol. 26,6 (2021). doi: https://doi.org/10.3390/molecules26061736
Sidor K, Berniak T, Łątka P, Rokicińska A, Michalik M, Kuśtrowski P. Tailoring Properties of Resol Resin-Derived Spherical Carbons for Adsorption of Phenol from Aqueous Solution. Molecules. 2021 Mar 19;26(6). doi: 10.3390/molecules26061736. PMID: 33808858; PMCID: PMC8003600.
Copy Download .nbib Format: NLM
Variant identification in BARD1, PRDM9, RCC1, and RECQL in patients with ovarian cancer by targeted next-generation sequencing of DNA pools.

Cancer prevention research (Philadelphia, Pa.)

Suszynska M, Ratajska M, Galka-Marciniak P, Ryszkowska A, Wydra D, Debniak J, Jasiak A, Wasag B, Cybulski C, Kozlowski P.
PMID: 34906988
Cancer Prev Res (Phila). 2021 Dec 14; doi: 10.1158/1940-6207.CAPR-21-0295. Epub 2021 Dec 14.

Several ovarian cancer susceptibility genes have been discovered, but more are likely to exist. In this study, we aimed to analyze knowledge-based selected genes, i.e., BARD1, PRDM9, RCC1, and RECQL, in which pathogenic germline variants have been reported in...

Cite
Suszynska M, Ratajska M, Galka-Marciniak P, et al. Variant identification in BARD1, PRDM9, RCC1, and RECQL in patients with ovarian cancer by targeted next-generation sequencing of DNA pools. Cancer Prev Res (Phila). 2021;doi: 10.1158/1940-6207.CAPR-21-0295.
Suszynska, M., Ratajska, M., Galka-Marciniak, P., Ryszkowska, A., Wydra, D., Debniak, J., Jasiak, A., Wasag, B., Cybulski, C., & Kozlowski, P. (2021). Variant identification in BARD1, PRDM9, RCC1, and RECQL in patients with ovarian cancer by targeted next-generation sequencing of DNA pools. Cancer prevention research (Philadelphia, Pa.), . https://doi.org/10.1158/1940-6207.CAPR-21-0295
Suszynska, Malwina, et al. "Variant identification in BARD1, PRDM9, RCC1, and RECQL in patients with ovarian cancer by targeted next-generation sequencing of DNA pools." Cancer prevention research (Philadelphia, Pa.) vol. (2021). doi: https://doi.org/10.1158/1940-6207.CAPR-21-0295
Suszynska M, Ratajska M, Galka-Marciniak P, Ryszkowska A, Wydra D, Debniak J, Jasiak A, Wasag B, Cybulski C, Kozlowski P. Variant identification in BARD1, PRDM9, RCC1, and RECQL in patients with ovarian cancer by targeted next-generation sequencing of DNA pools. Cancer Prev Res (Phila). 2021 Dec 14; doi: 10.1158/1940-6207.CAPR-21-0295. Epub 2021 Dec 14. PMID: 34906988.
Copy Download .nbib Format: NLM
Integrating Sex/Gender into Environmental Health Research: Development of a Conceptual Framework.

International journal of environmental research and public health

Bolte G, Jacke K, Groth K, Kraus U, Dandolo L, Fiedel L, Debiak M, Kolossa-Gehring M, Schneider A, Palm K.
PMID: 34831873
Int J Environ Res Public Health. 2021 Nov 18;18(22). doi: 10.3390/ijerph182212118.

There is a growing awareness about the need to comprehensively integrate sex and gender into health research in order to enhance the validity and significance of research results. An in-depth consideration of differential exposures and vulnerability is lacking, especially...

Cite
Bolte G, Jacke K, Groth K, et al. Integrating Sex/Gender into Environmental Health Research: Development of a Conceptual Framework. Int J Environ Res Public Health. 2021;18(22)doi: 10.3390/ijerph182212118.
Bolte, G., Jacke, K., Groth, K., Kraus, U., Dandolo, L., Fiedel, L., Debiak, M., Kolossa-Gehring, M., Schneider, A., & Palm, K. (2021). Integrating Sex/Gender into Environmental Health Research: Development of a Conceptual Framework. International journal of environmental research and public health, 18(22), . https://doi.org/10.3390/ijerph182212118
Bolte, Gabriele, et al. "Integrating Sex/Gender into Environmental Health Research: Development of a Conceptual Framework." International journal of environmental research and public health vol. 18,22 (2021). doi: https://doi.org/10.3390/ijerph182212118
Bolte G, Jacke K, Groth K, Kraus U, Dandolo L, Fiedel L, Debiak M, Kolossa-Gehring M, Schneider A, Palm K. Integrating Sex/Gender into Environmental Health Research: Development of a Conceptual Framework. Int J Environ Res Public Health. 2021 Nov 18;18(22). doi: 10.3390/ijerph182212118. PMID: 34831873; PMCID: PMC8621533.
Copy Download .nbib Format: NLM
Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?.

Cancers

Stempa K, Wokołorczyk D, Kluźniak W, Rogoża-Janiszewska E, Malińska K, Rudnicka H, Huzarski T, Gronwald J, Gliniewicz K, Dębniak T, Jakubowska A, Lener M, Tomiczek-Szwiec J, Domagała P, Suszynska M, Kozlowski P, Kluz T, Naczk M, Lubiński J, Narod SA, Akbari MR, Cybulski C, On Behalf Of The Polish Hereditary Prostate Cancer Consortium.
PMID: 34771627
Cancers (Basel). 2021 Oct 30;13(21). doi: 10.3390/cancers13215464.

The current cancer testing gene panels tend to be comprehensive rather than site-specific.

Cite
Stempa K, Wokołorczyk D, Kluźniak W, et al. Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?. Cancers (Basel). 2021;13(21)doi: 10.3390/cancers13215464.
Stempa, K., Wokołorczyk, D., Kluźniak, W., Rogoża-Janiszewska, E., Malińska, K., Rudnicka, H., Huzarski, T., Gronwald, J., Gliniewicz, K., Dębniak, T., Jakubowska, A., Lener, M., Tomiczek-Szwiec, J., Domagała, P., Suszynska, M., Kozlowski, P., Kluz, T., Naczk, M., Lubiński, J., Narod, S. A., Akbari, M. R., Cybulski, C., & On Behalf Of The Polish Hereditary Prostate Cancer Consortium. (2021). Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?. Cancers, 13(21), . https://doi.org/10.3390/cancers13215464
Stempa, Klaudia, et al. "Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?." Cancers vol. 13,21 (2021). doi: https://doi.org/10.3390/cancers13215464
Stempa K, Wokołorczyk D, Kluźniak W, Rogoża-Janiszewska E, Malińska K, Rudnicka H, Huzarski T, Gronwald J, Gliniewicz K, Dębniak T, Jakubowska A, Lener M, Tomiczek-Szwiec J, Domagała P, Suszynska M, Kozlowski P, Kluz T, Naczk M, Lubiński J, Narod SA, Akbari MR, Cybulski C, On Behalf Of The Polish Hereditary Prostate Cancer Consortium. Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?. Cancers (Basel). 2021 Oct 30;13(21). doi: 10.3390/cancers13215464. PMID: 34771627; PMCID: PMC8582358.
Copy Download .nbib Format: NLM
Familial malignant melanoma - overview.

Hereditary cancer in clinical practice

Debniak T.
PMID: 20233466
Hered Cancer Clin Pract. 2004 Jul 15;2(3):123-9. doi: 10.1186/1897-4287-2-3-123.

Approximately 3-15% of all malignant melanomas (MM) are familial cases. MM is a highly heterogeneous tumour type from a genetic perspective. Pedigrees with disease confined to a single generation of siblings or MM occurring among second- or third-degree relatives...

Cite
Debniak T. Familial malignant melanoma - overview. Hered Cancer Clin Pract. 2004;2(3):123-9doi: 10.1186/1897-4287-2-3-123.
Debniak, T. (2004). Familial malignant melanoma - overview. Hereditary cancer in clinical practice, 2(3), 123-9. https://doi.org/10.1186/1897-4287-2-3-123
Debniak, Tadeusz. "Familial malignant melanoma - overview." Hereditary cancer in clinical practice vol. 2,3 (2004): 123-9. doi: https://doi.org/10.1186/1897-4287-2-3-123
Debniak T. Familial malignant melanoma - overview. Hered Cancer Clin Pract. 2004 Jul 15;2(3):123-9. doi: 10.1186/1897-4287-2-3-123. PMID: 20233466; PMCID: PMC4392520.
Copy Download .nbib Format: NLM
Coverage of the genetic background of breast cancer in the polish population.

Hereditary cancer in clinical practice

Serrano-Fernández P, Górski B, Debniak T, Cybulski C, Byrski T, Huzarski T, Gronwald J, Jakubowska A, Oszurek O, Lubiński J.
PMID: 20223000
Hered Cancer Clin Pract. 2006 Nov 15;4(1):25-7. doi: 10.1186/1897-4287-4-1-25.

No abstract available.

Cite
Serrano-Fernández P, Górski B, Debniak T, et al. Coverage of the genetic background of breast cancer in the polish population. Hered Cancer Clin Pract. 2006;4(1):25-7doi: 10.1186/1897-4287-4-1-25.
Serrano-Fernández, P., Górski, B., Debniak, T., Cybulski, C., Byrski, T., Huzarski, T., Gronwald, J., Jakubowska, A., Oszurek, O., Lubiński, J. (2006). Coverage of the genetic background of breast cancer in the polish population. Hereditary cancer in clinical practice, 4(1), 25-7. https://doi.org/10.1186/1897-4287-4-1-25
Serrano-Fernández, Pablo, et al. "Coverage of the genetic background of breast cancer in the polish population." Hereditary cancer in clinical practice vol. 4,1 (2006): 25-7. doi: https://doi.org/10.1186/1897-4287-4-1-25
Serrano-Fernández P, Górski B, Debniak T, Cybulski C, Byrski T, Huzarski T, Gronwald J, Jakubowska A, Oszurek O, Lubiński J. Coverage of the genetic background of breast cancer in the polish population. Hered Cancer Clin Pract. 2006 Nov 15;4(1):25-7. doi: 10.1186/1897-4287-4-1-25. PMID: 20223000; PMCID: PMC3401916.
Copy Download .nbib Format: NLM
Inherited Variants in .

Cancers

Kluźniak W, Wokołorczyk D, Rusak B, Huzarski T, Kashyap A, Stempa K, Rudnicka H, Jakubowska A, Szwiec M, Morawska S, Gliniewicz K, Mordak K, Stawicka M, Jarkiewicz-Tretyn J, Cechowska M, Domagała P, Dębniak T, Lener M, Gronwald J, Lubiński J, Narod SA, Akbari MR, Cybulski C.
PMID: 31614901
Cancers (Basel). 2019 Oct 13;11(10). doi: 10.3390/cancers11101548.

Bloom Syndrome is a rare recessive disease which includes a susceptibility to various cancers. It is caused by homozygous mutations of the

Cite
Kluźniak W, Wokołorczyk D, Rusak B, et al. Inherited Variants in . Cancers (Basel). 2019;11(10)doi: 10.3390/cancers11101548.
Kluźniak, W., Wokołorczyk, D., Rusak, B., Huzarski, T., Kashyap, A., Stempa, K., Rudnicka, H., Jakubowska, A., Szwiec, M., Morawska, S., Gliniewicz, K., Mordak, K., Stawicka, M., Jarkiewicz-Tretyn, J., Cechowska, M., Domagała, P., Dębniak, T., Lener, M., Gronwald, J., Lubiński, J., Narod, S. A., Akbari, M. R., & Cybulski, C. (2019). Inherited Variants in . Cancers, 11(10), . https://doi.org/10.3390/cancers11101548
Kluźniak, Wojciech, et al. "Inherited Variants in ." Cancers vol. 11,10 (2019). doi: https://doi.org/10.3390/cancers11101548
Kluźniak W, Wokołorczyk D, Rusak B, Huzarski T, Kashyap A, Stempa K, Rudnicka H, Jakubowska A, Szwiec M, Morawska S, Gliniewicz K, Mordak K, Stawicka M, Jarkiewicz-Tretyn J, Cechowska M, Domagała P, Dębniak T, Lener M, Gronwald J, Lubiński J, Narod SA, Akbari MR, Cybulski C. Inherited Variants in . Cancers (Basel). 2019 Oct 13;11(10). doi: 10.3390/cancers11101548. PMID: 31614901; PMCID: PMC6826355.
Copy Download .nbib Format: NLM
Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland.

Cancers

Rogoża-Janiszewska E, Malińska K, Cybulski C, Jakubowska A, Gronwald J, Huzarski T, Lener M, Górski B, Kluźniak W, Rudnicka H, Akbari MR, Kashyap A, Narod SA, Lubiński J, Dębniak T, On Behalf Of The Polish Hereditary Breast Cancer Consortium.
PMID: 32824581
Cancers (Basel). 2020 Aug 17;12(8). doi: 10.3390/cancers12082321.

There are twenty recurrent mutations in six breast-cancer-predisposing genes in Poland (BRCA1, BRCA2, CHEK2, PALB2, NBN, and RECQL). The frequencies of the twenty alleles have not been measured in a large series of early-onset breast cancer patients from Poland...

Cite
Rogoża-Janiszewska E, Malińska K, Cybulski C, et al. Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland. Cancers (Basel). 2020;12(8)doi: 10.3390/cancers12082321.
Rogoża-Janiszewska, E., Malińska, K., Cybulski, C., Jakubowska, A., Gronwald, J., Huzarski, T., Lener, M., Górski, B., Kluźniak, W., Rudnicka, H., Akbari, M. R., Kashyap, A., Narod, S. A., Lubiński, J., Dębniak, T., & On Behalf Of The Polish Hereditary Breast Cancer Consortium. (2020). Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland. Cancers, 12(8), . https://doi.org/10.3390/cancers12082321
Rogoża-Janiszewska, Emilia, et al. "Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland." Cancers vol. 12,8 (2020). doi: https://doi.org/10.3390/cancers12082321
Rogoża-Janiszewska E, Malińska K, Cybulski C, Jakubowska A, Gronwald J, Huzarski T, Lener M, Górski B, Kluźniak W, Rudnicka H, Akbari MR, Kashyap A, Narod SA, Lubiński J, Dębniak T, On Behalf Of The Polish Hereditary Breast Cancer Consortium. Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland. Cancers (Basel). 2020 Aug 17;12(8). doi: 10.3390/cancers12082321. PMID: 32824581; PMCID: PMC7465341.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 43 entries